DOI: http://dx.doi.org/10.18203/2349-3933.ijam20192234

Assessment of liver involvement in type 2 diabetes mellitus using fibroscan® and correlation with risk factors

Alagesan ., Sairam Kumar

Abstract


Background: Non‐alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver injury. The most important predictor of mortality in NAFLD is the extent of liver fibrosis. Advanced liver fibrosis is associated with overall and liver related mortality. The upcoming non-invasive imaging modality for the evaluation of liver fibrosis is transient elastography (TE) (Fibro scan®). The aim of this study is to assess hepatopathy among diabetics using TE and to correlate the degree of hepatopathy with the associated risk factors.

Methods: Type 2 diabetes mellitus patients were assessed for liver stiffness using TE. Liver stiffness was correlated with the associated risk factors. Authors recruited 100 patients from diabetic clinic in tertiary care teaching hospital.

Results: About 55% of males and 39% of females had increased liver stiffness. 14% of males and 11% of females had severe fibrosis(F3-F4). Body mass index, waist circumference, fasting blood sugar levels, and liver enzymes, had significant positive correlation with liver stiffness whereas triglyceride levels, high-density lipoprotein levels, and duration of diabetes mellitus did not correlate with liver stiffness.

Conclusions: Diabetic patients have high prevalence of NAFLD and advanced fibrosis. Those with obesity and dyslipidaemia are at particularly high risk. Type 2 diabetes mellitus patients with hepatopathy can be easily identified using TE scan eliminating the need for liver biopsy. The establishment of a national program for the recognition of NAFLD is essential to reduce the risk of liver disease progression.


Keywords


Transient elastography, Fibro scan, Liver stiffness, Non‐alcoholic fatty liver disease, Type 2 diabetes mellitus

Full Text:

PDF

References


Joshi SR, Parikh RM. India; the diabetes capital of the world: Now heading towards hypertension. J Assoc Physic India. 2007;55:323.

Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28:339-50.

World health organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. World health organization.1999. Available at: http://www.who.int/iris/handle/10665/66040.

American diabetes association. Diagnosis and classification of diabetes mellitus. Diab Care 2014;37(1):S81-90.

Farrell GC, George J, Hall P, McCullough AJ. Overview: an introduction to NASH and related fatty liver disorders. Fatty liver disease. NASH and related disorders. Oxford: Blackwell Publishing. 2005:1-2.

Yoneda M, Fujita K, Inamori M, Nakajima A, Tamano M, Hiraishi H. Transient elastography in patients with non-alcoholic fatty liver disease. Gut. 2007;56(9):1330-1.

Pratyush DD, Tiwari S, Singh S, Singh SK. Waist circumference cutoff and its importance for diagnosis of metabolic syndrome in Asian Indians: A preliminary study. Ind J Endocrinol Metabol. 2012;16(1):112.

Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatol. 2007;45(4):846-54.

Friedman SL, Bansal MB. Reversal of hepatic fibrosis-fact or fantasy?. Hepatol. 2006;43:S82.

Cairns SR, Peters TJ. Biochemical analysis of hepatic lipid in alcoholic and diabetic and control subjects. Clinic Sci. 1983;65(6):645-2.

Ludwig J, Viggiano TR, Mcgill DB, Oh BJ. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. In Mayo clinic Proceed. 1980;55(7):434-8.

Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterol. 1999;116(6):1413-9.

Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterol. 2005;128(7):1898-06.

Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94(9):2467.

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatol. 2005;41(6):1313-21.

Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatol. 1990;12(5):1106.

Roulot D, Czernichow S, Le Clésiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol. 2008;48(4):606-13.

Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21(1):3-16.

Atan NA, Koushki M, Motedayen M, Dousti M, Sayehmiri F, Vafaee R, et al. Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2017;10(1):S1.

Kalra S, Vithalani M, Gulati G, Kulkarni C, Kadam Y, Pallivathukkal J, et al. Study of prevalence of nonalcoholic fatty liver disease in type 2 diabetes patients in India. J Assoc Physic India. 2013;61:448-53.

Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CE. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diab Res Clin Pract. 2009;84:84-91

Cheng PN, Chiu YC, Chiu HC, Chien SC. The application of liver stiffness measurement in residents without overt liver diseases through a community-based screening program. Med. 2016;95(12).

Yen YH, Chang KC, Tsai MC, Tseng PL, Lin MT, Wu CK, et al. Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease. J Formosan Med Assoc. 2018;117(4):268-75.

European association for the study of the liver, European association for the study of diabetes (EASD. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obesity Facts. 2016;9(2):65-90.

Prasetya IB, Hasan I, Wisnu W, Rumende CM. Prevalence and profile of fibrosis in diabetic patients with non-alcoholic fatty liver disease and the associated factors. Acta Medica Indonesiana. 2017;49(2):91-8.

Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998;93(1):44.

Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells. Hepatol. 1985;5(3):367-5.

Nalpas B, Vassault A, Guillou AL, Lesgourgues B, Ferry N, Lacour B, et al. Serum activity of mitochondrial aspartate aminotransferase: a sensitive marker of alcoholism with or without alcoholic hepatitis. Hepatol. 1984;4(5):893-6.

Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metabol. 2015;19(5):597.